Cargando…

New Therapeutic Strategies in Advanced Nonoperable or Metastatic HER2-positive Breast Cancer

Despite therapeutic gains in the treatment of HER2-positive (HER2: human epidermal growth factor receptor 2) advanced/metastatic breast cancer, there remains an urgent need for more effective treatment options. At present, there is no definitive approved standard therapy beyond second-line treatment...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lüftner, Diana, Peipp, Matthias
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Georg Thieme Verlag KG 2021
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8216785/ https://www.ncbi.nlm.nih.gov/pubmed/34168380 http://dx.doi.org/10.1055/a-1471-4063

Ejemplares similares

Beyond trastuzumab: novel therapeutic strategies in HER2-positive metastatic breast cancer
por: Tsang, R Y, et al.
Publicado: (2012)

More effective use of polymyxin-B hemoperfusion for nonoperation cases
por: Yahata, M, et al.
Publicado: (2014)

Cutibacteriumacnes Septic Arthritis of the Nonoperated Knee: A Case Report
por: Okoroha, Kelechi R., et al.
Publicado: (2017)

Advancing the Care of Women With HER2-Positive Metastatic Breast Cancer
por: Beasley, Marcie, et al.
Publicado: (2023)

Quantum Non-Markovian Environment-to-System Backflows of Information: Nonoperational vs. Operational Approaches
por: Budini, Adrián A.
Publicado: (2022)

Surrogate threshold effect based on a meta-analysis for the predictive value of progression-free survival for overall survival in hormone receptor-positive, HER2-negative metastatic breast cancer
por: Lux, Michael Patrick, et al.
Publicado: (2019)

Clinical Impact of New Treatment Strategies for HER2-Positive Metastatic Breast Cancer Patients with Resistance to Classical Anti-HER Therapies
por: Tapia, Marta, et al.
Publicado: (2023)

Therapy Landscape in Patients with Metastatic HER2-Positive Breast Cancer: Data from the PRAEGNANT Real-World Breast Cancer Registry
por: Lux, Michael P., et al.
Publicado: (2018)

Recent advances in systemic therapy: Advances in systemic therapy for HER2-positive metastatic breast cancer
por: Morrow, Phuong Khanh H, et al.
Publicado: (2009)

New Therapeutics in HER2-Positive Advanced Breast Cancer: Towards a Change in Clinical Practices?
por: Mezni, Essia, et al.
Publicado: (2020)

Systemic therapy of metastatic breast cancer: a plea for confirmation of subtypes by genomic assays
por: Lüftner, Diana
Publicado: (2022)

New Agents for the Management of Advanced HER2-Positive Breast Cancer
por: Royce, Melanie, et al.
Publicado: (2016)

Treating Advanced Unresectable or Metastatic HER2-Positive Breast Cancer: A Spotlight on Tucatinib
por: Ulrich, Lara, et al.
Publicado: (2021)

Clinical Outcomes of the Marginal Ulcer Bleeding after Gastrectomy: As Compared to the Peptic Ulcer Bleeding with Nonoperated Stomach
por: Chung, Woo Chul, et al.
Publicado: (2012)

Mechanisms of Resistance to Trastuzumab and Novel Therapeutic Strategies in HER2-Positive Breast Cancer
por: Wong, Andrea L. A., et al.
Publicado: (2012)

Immunotherapy for HER2-positive breast cancer: recent advances and combination therapeutic approaches
por: Ayoub, Nehad M, et al.
Publicado: (2019)

Current therapeutic strategies of anti-HER2 treatment in advanced breast cancer patients
por: Huszno, Joanna, et al.
Publicado: (2016)

HER2-positive breast cancer: new therapeutic frontiers and overcoming resistance
por: Pernas, Sonia, et al.
Publicado: (2019)

The prognostic relevance of HER2-positivity gain in metastatic breast cancer in the ChangeHER trial
por: Pizzuti, Laura, et al.
Publicado: (2021)

Tucatinib approval by EMA expands options for HER2-positive locally advanced or metastatic breast cancer
por: Corti, C., et al.
Publicado: (2021)

Ado-Trastuzumab Emtansine in Metastatic HER2-Positive Breast Cancer
por: Callahan, Rena
Publicado: (2014)

ASCO 2018: highlights in HER2-positive metastatic breast cancer
por: Bartsch, Rupert, et al.
Publicado: (2018)

Trastuzumab beyond progression in HER2‐positive metastatic breast cancer
por: Al‐Naqqash, Manwar, et al.
Publicado: (2021)

HER2 and uPAR cooperativity contribute to metastatic phenotype of HER2-positive breast cancer
por: Chandran, Vineesh Indira, et al.
Publicado: (2015)

Anti-HER2 Drugs for the Treatment of Advanced HER2 Positive Breast Cancer
por: Stanowicka-Grada, Malwina, et al.
Publicado: (2023)

Clinical utility of serum HER2/neu in monitoring and prediction of progression-free survival in metastatic breast cancer patients treated with trastuzumab-based therapies
por: Esteva, Francisco J, et al.
Publicado: (2005)

Pyrotinib as a therapeutic for HER2-positive breast cancer
por: Kioutchoukova, Ivelina, et al.
Publicado: (2023)

Long-term survivor characteristics in HER2-positive metastatic breast cancer from registHER
por: Yardley, D A, et al.
Publicado: (2014)

Impaired neuromuscular control up to postoperative 1 year in operated and nonoperated knees after anterior cruciate ligament reconstruction
por: Lee, Jin Hyuck, et al.
Publicado: (2019)

Therapeutic Advances and Challenges in the Management of HER2-Positive Gastroesophageal Cancers
por: Chuang, Jeremy, et al.
Publicado: (2022)

The antitumor immune response in HER-2 positive, metastatic breast cancer patients
por: Juranic, Zorica D, et al.
Publicado: (2005)

Trastuzumab for HER2-Positive Metastatic Breast Cancer: Clinical and Economic Considerations
por: Jeyakumar, Alwin, et al.
Publicado: (2012)

Current and Emerging Therapies for HER2-Positive Women With Metastatic Breast Cancer
por: Porter, Karlyn, et al.
Publicado: (2017)

Genomic characteristics of trastuzumab-resistant Her2-positive metastatic breast cancer
por: de Oliveira Taveira, Mateus, et al.
Publicado: (2017)

Neu Perspectives, Therapies, and Challenges for Metastatic HER2-Positive Breast Cancer
por: Salkeni, Mohamad Adham, et al.
Publicado: (2021)

Developments in the Management of Metastatic HER2-Positive Breast Cancer: A Review
por: Lebert, Julie, et al.
Publicado: (2022)

How we treat patients with metastatic HER2-positive breast cancer
por: Nader-Marta, G., et al.
Publicado: (2022)

HER2-Positive Metastatic Breast Cancer: Available Treatments and Current Developments
por: Essadi, Ismail, et al.
Publicado: (2023)

Sacituzumab Govitecan in HR-positive HER2-negative metastatic breast cancer
por: Nardin, Simone, et al.
Publicado: (2023)

Recent advances in systemic therapy. When HER2 is not the target: advances in the treatment of HER2-negative metastatic breast cancer
por: Miles, David W
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_8ibcb1ik2nmrosgleje0e51gc3